<DOC>
	<DOCNO>NCT00243113</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , docetaxel work different way stop growth tumor cell , either kill cell stop divide . Radiation therapy use high-energy x-ray kill tumor cell . Giving docetaxel together radiation therapy may kill tumor cell . PURPOSE : This phase II trial study well give docetaxel together radiation therapy work treat patient stage II stage III cancer larynx hypopharynx .</brief_summary>
	<brief_title>Docetaxel Radiation Therapy Treating Patients With Stage II Stage III Cancer Larynx Hypopharynx</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine objective response primary tumor patient stage II III squamous cell carcinoma larynx hypopharynx treat docetaxel radiotherapy . Secondary - Determine local relapse-free survival patient treat regimen . - Determine larynx-preservation survival patient treat regimen . - Determine overall survival patient treat regimen . - Determine protocol completion rate patient treat regimen . - Determine adverse effect regimen patient . OUTLINE : This multicenter study . Patients receive docetaxel IV 1 hour day 1 , 8 , 15 , 22 , 29 undergo radiotherapy day 1-5 , 8-12 , 15-19 , 22-26 , 29-33 . PROJECTED ACCRUAL : A total 25-50 patient accrue study .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm squamous cell carcinoma larynx hypopharynx Stage II III disease Solitary lymph node metastasis locate level IIIII allow Age 70 OR meet 1 follow criterion : Creatinine clearance 3060 mL/min History platinum allergy Diagnosis unstable angina Ineligible systemic chemotherapy , include highdose platinumcontaining regimen PATIENT CHARACTERISTICS : Age See Disease Characteristics Performance status ECOG 02 Life expectancy Not specify Hematopoietic WBC &gt; 3,000/mm^3 Neutrophil count &gt; 1,500/mm^3 Hemoglobin &gt; 10 g/dL Platelet count &gt; 100,000/mm^3 Hepatic AST ALT ≤ 2.0 time upper limit normal Bilirubin &lt; 2.0 mg/dL No severe liver disease Renal See Disease Characteristics Creatinine clearance ≥ 30 mL/min No severe renal disease Pulmonary No severe pulmonary disease Other No severe neurologic disease PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy No prior systemic chemotherapy Endocrine therapy Not specify Radiotherapy No prior radiotherapy Surgery No prior surgery</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2008</verification_date>
	<keyword>stage II squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage II squamous cell carcinoma larynx</keyword>
	<keyword>stage III squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage III squamous cell carcinoma larynx</keyword>
</DOC>